Yumanity Therapeutics (NASDAQ:YMTX) Shares Down 3.4%

Yumanity Therapeutics, Inc. (NASDAQ:YMTXGet Free Report) shares fell 3.4% during mid-day trading on Wednesday . The stock traded as low as $3.90 and last traded at $3.98. 13,363 shares traded hands during trading, a decline of 97% from the average session volume of 473,083 shares. The stock had previously closed at $4.12.

Yumanity Therapeutics Stock Performance

The stock has a market capitalization of $43.21 million, a P/E ratio of -1.33 and a beta of 0.32. The stock has a 50-day moving average price of $3.06 and a two-hundred day moving average price of $2.88.

Institutional Investors Weigh In On Yumanity Therapeutics

Large investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in shares of Yumanity Therapeutics in the 2nd quarter worth approximately $155,000. Renaissance Technologies LLC grew its position in shares of Yumanity Therapeutics by 16.7% in the 2nd quarter. Renaissance Technologies LLC now owns 70,508 shares of the company’s stock worth $128,000 after buying an additional 10,100 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Yumanity Therapeutics by 54.0% in the 3rd quarter. Citadel Advisors LLC now owns 49,543 shares of the company’s stock valued at $78,000 after purchasing an additional 17,364 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Yumanity Therapeutics in the 1st quarter valued at approximately $35,000. 25.10% of the stock is currently owned by institutional investors.

Yumanity Therapeutics Company Profile

(Get Free Report)

Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.

Recommended Stories

Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.